Goldman Sachs’s CRISPR Therapeutics CRSP Stock Holding History

Goldman Sachs’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-7,500	Closed	-$511K	–	5688
2024 Q1	$511K	Sell	7,500 -21,600	-74%	-$1.55M	﹤0.01%	4738
2023 Q4	$1.82M	Sell	29,100 -41,900	-59%	-$2.32M	﹤0.01%	3999
2023 Q3	$3.22M	Hold	71,000	–	–	﹤0.01%	3373
2023 Q2	$3.99M	Hold	71,000	–	–	﹤0.01%	3301
2023 Q1	$3.21M	Sell	71,000 -95,700	-57%	-$4.65M	﹤0.01%	3468
2022 Q4	$6.78M	Sell	166,700 -161,800	-49%	-$8.58M	﹤0.01%	2919
2022 Q3	$21.5M	Buy	328,500 +185,000	+129%	+$13.4M	0.01%	1800
2022 Q2	$8.72M	Buy	+143,500	New	+$8.44M	﹤0.01%	2646
2021 Q2	–	Sell	-13,200	Closed	-$1.61M	–	6241
2021 Q1	$1.61M	Buy	13,200 +4,000	+43%	+$604K	﹤0.01%	4200
2020 Q4	$1.41M	Buy	+9,200	New	+$1.09M	﹤0.01%	3973
2020 Q1	–	Sell	-11,000	Closed	-$670K	–	5248
2019 Q4	$670K	Buy	+11,000	New	+$601K	﹤0.01%	4347
2018 Q4	–	Sell	-1,000	Closed	-$44K	–	5289
2018 Q3	$44K	Sell	1,000 -500	-33%	-$26.2K	﹤0.01%	5312
2018 Q2	$88K	Buy	+1,500	New	+$85.5K	﹤0.01%	5241

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GSK plc London $602M AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Goldman Sachs's CRSP Position: Q2 2026 in Review

Goldman Sachs reduced its CRISPR Therapeutics (CRSP) stake by 34% in Q2 2026, selling an estimated $7.48M and leaving 272,372 shares worth $14.9M. The position accounts for ﹤0.01% of the portfolio, ranked #2918.

Goldman Sachs first reported a position in CRSP in Q4 2017 and has held it in 35 quarters since. The position peaked at $48.7M in Q3 2022. 523 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

Goldman Sachs held 272,372 shares of CRISPR Therapeutics worth $14.9M as of Q2 2026.
Goldman Sachs sold 141,848 CRISPR Therapeutics shares in Q2 2026, an estimated $7.48M.
CRISPR Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #2918 holding.
Goldman Sachs first reported a position in CRISPR Therapeutics in Q4 2017 and has held it in 35 quarters since.
Goldman Sachs's CRISPR Therapeutics position peaked at $48.7M in Q3 2022.
523 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.